APAC Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

Asia-Pacific fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific fibrotic diseases treatment market are:

Rising prevalence of fibrotic diseases

Technological advancement in the treatment of fibrosis diseases

Market Players:

Some of the key market players in the Asia-Pacific fibrotic diseases treatment market are listed below:

Boehringer Ingelheim International GmbH

AbbVie Inc.

Bristol-Myers Squibb Company

Gilead Sciences, Inc.

Teva Pharmaceutical Industries Ltd.

Sandoz International GmbH

1 INTRODUCTION 33

1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48

3 EXECUTIVE SUMMARY 49

4 PREMIUM INSIGHTS 51

4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53

5 EPIDEMIOLOGY 54

5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55

6 INDUSTRY INSIGHTS 56

6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58

7 MERGERS AND ACQUISITIONS 60

7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60

8 PIPELINE ANALYSIS 61

8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61

9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62

9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63

10 MARKET OVERVIEW 64

10.1 DRIVERS 66
- 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
- 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
- 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
- 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
- 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
- 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
- 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
- 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
- 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69

11 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70

11.1 OVERVIEW 71
11.2 MEDICATION 73
- 11.2.1 INTEDANIB (OFEV) 74
- 11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76

12 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77

12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84

13 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85

13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91

14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92

14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97

15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98

15.1 ASIA-PACIFIC 99
- 15.1.1 JAPAN 106
- 15.1.2 CHINA 108
- 15.1.3 INDIA 110
- 15.1.4 SOUTH KOREA 112
- 15.1.5 AUSTRALIA 114
- 15.1.6 SINGAPORE 116
- 15.1.7 THAILAND 118
- 15.1.8 MALAYSIA 120
- 15.1.9 INDONESIA 122
- 15.1.10 PHILIPPINES 124
- 15.1.11 VIETNAM 126
- 15.1.12 TAIWAN 128
- 15.1.13 REST OF ASIA-PACIFIC 130

16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 131

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 131

17 SWOT ANALYSIS 132

18 COMPANY PROFILE 133

18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 133
- 18.1.1 COMPANY SNAPSHOT 133
- 18.1.2 REVENUE ANALYSIS 133
- 18.1.3 COMPANY SHARE ANALYSIS 134
- 18.1.4 PRODUCT PORTFOLIO 134
- 18.1.5 RECENT DEVELOPMENTS 134
18.2 GENENTECH, INC. 135
- 18.2.1 COMPANY SNAPSHOT 135
- 18.2.2 COMPANY SHARE ANALYSIS 135
- 18.2.3 PRODUCT PORTFOLIO 136
- 18.2.4 RECENT DEVELOPMENTS 136
18.3 SANDOZ INTERNATIONAL GMBH 137
- 18.3.1 COMPANY SNAPSHOT 137
- 18.3.2 COMPANY SHARE ANALYSIS 137
- 18.3.3 PRODUCT PORTFOLIO 138
- 18.3.4 RECENT DEVELOPMENTS 138
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 139
- 18.4.1 COMPANY SNAPSHOT 139
- 18.4.2 REVENUE ANALYSIS 139
- 18.4.3 COMPANY SHARE ANALYSIS 140
- 18.4.4 PRODUCT PORTFOLIO 140
- 18.4.5 RECENT DEVELOPMENTS 140
18.5 ACCORD HEALTHCARE U.S. 141
- 18.5.1 COMPANY SNAPSHOT 141
- 18.5.2 COMPANY SHARE ANALYSIS 141
- 18.5.3 PRODUCT PORTFOLIO 142
- 18.5.4 RECENT DEVELOPMENTS 142
18.6 ABBVIE INC. 143
- 18.6.1 COMPANY SNAPSHOT 143
- 18.6.2 REVENUE ANALYSIS 143
- 18.6.3 PRODUCT PORTFOLIO 144
- 18.6.4 RECENT DEVELOPMENTS 144
18.7 ALPINE IMMUNE SCIENCES 145
- 18.7.1 COMPANY SNAPSHOT 145
- 18.7.2 REVENUE ANALYSIS 145
- 18.7.3 PRODUCT PORTFOLIO 146
- 18.7.4 RECENT DEVELOPMENTS 146
18.8 BELLBROOK LABS 147
- 18.8.1 COMPANY SNAPSHOT 147
- 18.8.2 PRODUCT PORTFOLIO 147
- 18.8.3 RECENT DEVELOPMENTS 147
18.9 BIOMX 148
- 18.9.1 COMPANY SNAPSHOT 148
- 18.9.2 REVENUE ANALYSIS 148
- 18.9.3 PRODUCT PORTFOLIO 149
- 18.9.4 RECENT DEVELOPMENTS 149
18.10 BRISTOL-MYERS SQUIBB COMPANY 150
- 18.10.1 COMPANY SNAPSHOT 150
- 18.10.2 REVENUE ANALYSIS 150
- 18.10.3 PRODUCT PORTFOLIO 151
- 18.10.4 RECENT DEVELOPMENTS 151
18.11 CAMBER PHARMACEUTICALS, INC. 152
- 18.11.1 COMPANY SNAPSHOT 152
- 18.11.2 PRODUCT PORTFOLIO 152
- 18.11.3 RECENT DEVELOPMENTS 152
18.12 ENVEDA 153
- 18.12.1 COMPANY SNAPSHOT 153
- 18.12.2 PRODUCT PORTFOLIO 153
- 18.12.3 RECENT DEVELOPMENTS 153
18.13 GILEAD SCIENCES, INC. 154
- 18.13.1 COMPANY SNAPSHOT 154
- 18.13.2 REVENUE ANALYSIS 154
- 18.13.3 PRODUCT PORTFOLIO 155
- 18.13.4 RECENT DEVELOPMENTS 155
18.14 INTERCEPT PHARMACEUTICALS, INC. 156
- 18.14.1 COMPANY SNAPSHOT 156
- 18.14.2 REVENUE ANALYSIS 156
- 18.14.3 PRODUCT PORTFOLIO 157
- 18.14.4 RECENT DEVELOPMENTS 157
18.15 KITHER BIOTECH S.R.L. 158
- 18.15.1 COMPANY SNAPSHOT 158
- 18.15.2 PRODUCT PORTFOLIO 158
- 18.15.3 RECENT DEVELOPMENTS 158
18.16 PHARMAXIS LTD 159
- 18.16.1 COMPANY SNAPSHOT 159
- 18.16.2 REVENUE ANALYSIS 159
- 18.16.3 PRODUCT PORTFOLIO 160
- 18.16.4 RECENT DEVELOPMENTS 160
18.17 REDX PHARMA PLC. 161
- 18.17.1 COMPANY SNAPSHOT 161
- 18.17.2 REVENUE ANALYSIS 161
- 18.17.3 PRODUCT PORTFOLIO 162
- 18.17.4 RECENT DEVELOPMENTS 162
18.18 VERONA PHARMA PLC 163
- 18.18.1 COMPANY SNAPSHOT 163
- 18.18.2 REVENUE ANALYSIS 163
- 18.18.3 PRODUCT PORTFOLIO 164
- 18.18.4 RECENT DEVELOPMENTS 164

19 QUESTIONNAIRE 165

20 RELATED REPORTS 168

LIST OF TABLES

TABLE 1 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 46
TABLE 2 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 58
TABLE 3 ASIA PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 4 ASIA PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 59
TABLE 5 ASIA PACIFIC ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 6 ASIA PACIFIC OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 7 ASIA PACIFIC OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 8 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 65
TABLE 9 ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 10 ASIA PACIFIC HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 11 ASIA PACIFIC RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 12 ASIA PACIFIC CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 13 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 73
TABLE 15 ASIA PACIFIC HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 16 ASIA PACIFIC SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 17 ASIA PACIFIC ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 18 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 19 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 80
TABLE 20 ASIA PACIFIC HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 21 ASIA PACIFIC RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 22 ASIA PACIFIC OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 23 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 88
TABLE 24 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 88
TABLE 25 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 89
TABLE 26 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 89
TABLE 27 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 89
TABLE 28 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 89
TABLE 29 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 90
TABLE 30 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 90
TABLE 31 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 91
TABLE 32 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 91
TABLE 33 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 91
TABLE 34 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 91
TABLE 35 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 92
TABLE 36 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 92
TABLE 37 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 92
TABLE 38 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 93
TABLE 39 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 93
TABLE 40 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 93
TABLE 41 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 93
TABLE 42 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 94
TABLE 43 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 94
TABLE 44 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 94
TABLE 45 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 95
TABLE 46 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 95
TABLE 47 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 95
TABLE 48 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 95
TABLE 49 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 96
TABLE 50 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 96
TABLE 51 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 96
TABLE 52 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 97
TABLE 53 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 97
TABLE 54 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 97
TABLE 55 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 97
TABLE 56 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 98
TABLE 57 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 98
TABLE 58 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
TABLE 59 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 99
TABLE 60 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 99
TABLE 61 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 99
TABLE 62 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 99
TABLE 63 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 100
TABLE 64 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 100
TABLE 65 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 100
TABLE 66 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 101
TABLE 67 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 101
TABLE 68 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 101
TABLE 69 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 101
TABLE 70 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 102
TABLE 71 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 102
TABLE 72 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 102
TABLE 73 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 103
TABLE 74 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 103
TABLE 75 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 103
TABLE 76 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 103
TABLE 77 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 104
TABLE 78 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 104
TABLE 79 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 104
TABLE 80 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 105
TABLE 81 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 105
TABLE 82 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 105
TABLE 83 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 105
TABLE 84 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 106
TABLE 85 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 106
TABLE 86 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 106
TABLE 87 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 107
TABLE 88 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 107
TABLE 89 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 107
TABLE 90 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 107
TABLE 91 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 108
TABLE 92 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 108
TABLE 93 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 108
TABLE 94 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 109
TABLE 95 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 109
TABLE 96 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 109
TABLE 97 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 109
TABLE 98 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 110
TABLE 99 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
TABLE 100 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 110
TABLE 101 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 111
TABLE 102 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 111
TABLE 103 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 111
TABLE 104 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 111
TABLE 105 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 112
TABLE 106 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
TABLE 107 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 108 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 113
TABLE 109 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 113
TABLE 110 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 113
TABLE 111 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 113
TABLE 112 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 114
TABLE 113 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 114 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 115 REST OF ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 115

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 21
FIGURE 2 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: DATA TRIANGULATION 24
FIGURE 3 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: DROC ANALYSIS 25
FIGURE 4 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 26
FIGURE 5 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 26
FIGURE 6 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: DBMR MARKET POSITION GRID 29
FIGURE 8 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: MARKET END USER COVERAGE GRID 30
FIGURE 9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET : VENDOR SHARE ANALYSIS 31
FIGURE 10 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 34
FIGURE 11 RISING PREVALENCE OF FIBROTIC DISEASES IS EXPECTED TO DRIVE THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET GROWTH IN THE FORECAST PERIOD 35
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET IN 2023 & 2030 35
FIGURE 13 PATIENT FLOW DIAGRAM 43
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET 49
FIGURE 15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2022 55
FIGURE 16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2023-2030 (USD THOUSAND) 56
FIGURE 17 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT CAGR (2023-2030) 56
FIGURE 18 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT LIFELINE CURVE 57
FIGURE 19 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2022 62
FIGURE 20 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND) 63
FIGURE 21 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, CAGR (2023-2030) 63
FIGURE 22 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE 64
FIGURE 23 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2022 70
FIGURE 24 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 71
FIGURE 25 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, CAGR (2023-2030) 71
FIGURE 26 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY END USER, LIFELINE CURVE 72
FIGURE 27 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 77
FIGURE 28 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 78
FIGURE 29 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 78
FIGURE 30 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 79
FIGURE 31 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 84
FIGURE 32 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 85
FIGURE 33 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 85
FIGURE 34 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 86
FIGURE 35 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 86
FIGURE 36 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 115